Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-3-23
pubmed:abstractText
Beta-catenin has a crucial role in cell-cell adhesion as well as a signaling role as a member of the Wnt pathway. The aim of this study was to examine the clinicopathological and prognostic value of phosphorylated beta-catenin, as well as its relation to the tumors' phenotype, in breast cancer. Immunohistochemistry was applied on 141 paraffin-embedded breast tissue specimens for the detection of phospho-beta-catenin, ER, PR, c-erbB-2, p53, Ki-67, bcl-2, uPAR and TIMP-1. For each case, a phospho-beta-catenin index was determined by image analysis. Phospho-beta-catenin staining was detected in the cytoplasm and the nucleus of the malignant cells. Cytoplasmic phospho-beta-catenin was statistically higher in carcinomas of smaller tumor size (P = 0.030), lower stage (P = 0.026), decreased Ki-67 and high c-erbB-2 immunoreactivity (P = 0.052 and P = 0.037, respectively). Nuclear phospho-beta-catenin showed a parallel correlation with ER and ERbeta (P = 0.022 and P = 0.043, respectively), bcl-2 (P = 0.042), uPAR in cancer cells (P = 0.041) and TIMP-1, although the correlation was borderline (P = 0.066). Cytoplasmic phospho-beta-catenin was found to be independently correlated with prolonged disease-free and overall survival (P = 0.046 and P = 0.002, respectively), whereas nuclear localization was correlated with a shortened overall survival (P = 0.046). In conclusion, phospho-beta-catenin may have a different involvement in invasive breast carcinomas, according to its subcellular distribution. Nuclear localization seems to be related to an aggressive tumor phenotype, negatively affecting patients' overall survival, whereas cytoplasmic localization is associated with a favorable tumor phenotype and a longer disease-free and overall survival.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0893-3952
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
556-63
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16474376-Adult, pubmed-meshheading:16474376-Aged, pubmed-meshheading:16474376-Aged, 80 and over, pubmed-meshheading:16474376-Breast Neoplasms, pubmed-meshheading:16474376-Cell Nucleus, pubmed-meshheading:16474376-Cytoplasm, pubmed-meshheading:16474376-Female, pubmed-meshheading:16474376-Humans, pubmed-meshheading:16474376-Immunohistochemistry, pubmed-meshheading:16474376-Ki-67 Antigen, pubmed-meshheading:16474376-Middle Aged, pubmed-meshheading:16474376-Neoplasm Invasiveness, pubmed-meshheading:16474376-Phosphoproteins, pubmed-meshheading:16474376-Phosphorylation, pubmed-meshheading:16474376-Prognosis, pubmed-meshheading:16474376-Receptor, erbB-2, pubmed-meshheading:16474376-Receptors, Estrogen, pubmed-meshheading:16474376-Survival Analysis, pubmed-meshheading:16474376-beta Catenin
pubmed:year
2006
pubmed:articleTitle
Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome.
pubmed:affiliation
Department of Pathology, Attikon Hospital, Athens, Greece. lnakopou@cc.uoa.gr
pubmed:publicationType
Journal Article